A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed.
A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed.
复制标题
一项对患有难治性抑郁症 (TRD) 或有 TRD 病史且有反应但后来复发的门诊患者进行舍曲林的试点、开放研究。
DOI：
10.1097/00004850-200309000-00006
复制
发表时间：
2003
影响因子：
2.6
通讯作者：
Nierenberg,AndrewA
中科院分区：
文献类型：
--
作者：
Papakostas,GeorgeI;Petersen,Timothy;Worthington,JohnJ;Roffi,PamelaA;Alpert,JonathanE;Fava,Maurizio;Nierenberg,AndrewA
While most depressed patients are prescribed a selective serotonin reuptake inhibitor (SSRI) as an initial treatment, the use of SSRIs as a second or third-line treatment for depression is not as prevalent. This trial assessed the efficacy of sertraline for patients with treatment-resistant depression (TRD) or patients with a history of TRD who responded but later relapsed. Twelve patients with TRD who had not responded to a number of antidepressant trials (n= 7), or had responded but subsequently suffered a relapse (n= 5), were enrolled in an 8-week, open trial of sertraline. Both a completer analysis (n= 6) and an intent-to-treat (ITT) analysis (n= 12) were performed to evaluate sertraline response rates. Using a completer analysis, four patients (66.6%) were classified as responders; one (16.7%) as a partial responder and one (16.7%) as a non-responder. An ITT analysis resulted in five (41.7%) patients being classified as responders; one (8.3%) as a partial responder and six (50%) as non-responders. Of the four responders in the completer analysis, three (50%) achieved remission. Of the five responders in the ITT analysis, four (33.3%) achieved remission. Overall, two of seven (28.6%) non-responders and three of five (60.0%) relapsers responded to sertraline. The present results suggest the potential utility of sertraline for patients with TRD, or those with a history of TRD who responded but later relapsed, and warrant larger, placebo-controlled studies to further explore the potential role of sertraline for such patients.
